Cargando…

Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes

BACKGROUND: Majority of chondrosarcomas are associated with a number of genetic alterations, including somatic mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 genes, but the downstream effects of these mutated enzymes on cellular metabolism and tumor energetics are unknown. As IDH mutations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pathmanapan, Sinthu, Ilkayeva, Olga, Martin, John T., Loe, Adrian Kwan Ho, Zhang, Hongyuan, Zhang, Guo-Fang, Newgard, Christopher B., Wunder, Jay S., Alman, Benjamin A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992867/ https://www.ncbi.nlm.nih.gov/pubmed/33762012 http://dx.doi.org/10.1186/s40170-021-00247-8

Ejemplares similares

Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation
por: Pathmanapan, Sinthu, et al.
Publicado: (2023)

Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth
por: Li, Luyuan, et al.
Publicado: (2020)

Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
por: Nakagawa, Makoto, et al.
Publicado: (2022)

Oligosarcomas, IDH-mutant are distinct and aggressive
por: Suwala, Abigail K., et al.
Publicado: (2021)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

CyTOF Analysis Reveals a Distinct Immunosuppressive Microenvironment in IDH Mutant Anaplastic Gliomas
por: Fu, Weilun, et al.
Publicado: (2021)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
por: Khurshed, Mohammed, et al.
Publicado: (2018)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Induction of sarcomas by mutant IDH2
por: Lu, Chao, et al.
Publicado: (2013)

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
por: Farshidfar, Farshad, et al.
Publicado: (2017)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
por: Suijker, Johnny, et al.
Publicado: (2015)

IDH Mutations in Chondrosarcoma: Case Closed or Not?
por: Venneker, Sanne, et al.
Publicado: (2023)

Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks
por: Li, Kay Ka-Wai, et al.
Publicado: (2019)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

Mismatch repair–deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome
por: Tan, Hao, et al.
Publicado: (2023)

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
por: Popovici-Muller, Janeta, et al.
Publicado: (2018)

Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations
por: Zhang, Hongyuan, et al.
Publicado: (2022)

Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012)

Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM
por: Pasquini, Luca, et al.
Publicado: (2021)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Recent advances of IDH1 mutant inhibitor in cancer therapy
por: Tian, Wangqi, et al.
Publicado: (2022)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells
por: Viswanath, Pavithra, et al.
Publicado: (2016)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015)

Mutant IDH1 Promotes Glioma Formation In Vivo
por: Philip, Beatrice, et al.
Publicado: (2018)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

Malignant Progression of an IDH Mutant Brainstem Glioma in Adult
por: SANO, Kenshi, et al.
Publicado: (2021)

Proteome-based insights for IDH-mutant glioma classification
por: Leu, Severina, et al.
Publicado: (2023)

Mutant IDH in Gliomas: Role in Cancer and Treatment Options
por: Solomou, Georgios, et al.
Publicado: (2023)

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
por: Chaturvedi, A, et al.
Publicado: (2017)

The ezh2(sa1199) mutant zebrafish display no distinct phenotype
por: San, Bilge, et al.
Publicado: (2019)

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
por: Li, Luyuan, et al.
Publicado: (2015)

In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
por: Chaturvedi, Anuhar, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3qm3sce8ni4asospjgca5oegbk